Larimar Therapeutics, Inc.
LRMR evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $411.4M
- Next Catalyst:
- Phase3_Start · Oct 26, 2026
What it means
What to watch
Prepared research question
What matters most for LRMR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LRMR
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a protein replacement therapy for Friedreich's ataxia, with regulatory designations for accelerated approval and a Phase 3 trial underway.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials · 1 catalyst for Larimar Therapeutics, Inc..
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a protein replacement therapy for Friedreich's ataxia, with regulatory designations for accelerated approval and a Phase 3 trial underway.
- Lead candidate nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to mitochondria in Friedreich's ataxia patients [sec_mda · as of 2026-08-04].
- Nomlabofusp has received FDA Fast Track, Rare Pediatric Disease, and Breakthrough Therapy Designations, plus EMA PRIME and UK MHRA ILAP access [sec_mda · as of 2026-08-04].
- Cash, cash equivalents, and marketable securities were $156.3 million as of June 30, 2026 [sec_mda · as of 2026-08-04]; latest reported financials (as of 2026-06-30) show cash & equivalents of $92.7M [sec].
- Accumulated deficit reached $497.2 million as of June 30, 2026, with net losses of $32.8M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-04].
- A Phase 3 randomized, double-blind, placebo-controlled study of nomlabofusp started in August 2026 [catalyst].
What works
- Multiple FDA and international regulatory designations (Fast Track, Breakthrough Therapy, Rare Pediatric Disease, PRIME, ILAP) may accelerate development and review [sec_mda · as of 2026-08-04].
- FDA agreed in principle that skin FXN concentration could serve as a reasonably likely surrogate endpoint for accelerated approval, potentially shortening the path to market [sec_mda · as of 2026-03-19].
- The company's CPP technology platform may enable targeting of other intracellular rare diseases beyond FA [sec_mda · as of 2026-03-19].
What to weigh
- The company has no approved products and expects no product sales for several years, if at all [sec_mda · as of 2026-05-14].
- Accumulated deficit of $497.2 million as of June 30, 2026, with ongoing operating losses [sec_mda · as of 2026-08-04].
- Clinical development is subject to delays; the company may need to reduce expenditures if trials encounter unexpected delays [sec_mda · as of 2026-08-04].
- Reliance on a novel surrogate endpoint (skin FXN) for accelerated approval carries regulatory risk; FDA stated safety database adequacy will be reviewed at BLA submission [sec_mda · as of 2026-03-19].
From the filings
Quoted directly from source documents.
Nomlabofusp is designed to deliver frataxin to mitochondria in FA patients.
“Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia ("FA").”
SEC MD&A · August 4, 2026
Cash position as of June 30, 2026 was $156.3 million.
“As of June 30, 2026, we had approximately $156.3 million of cash, cash equivalents and marketable securities.”
SEC MD&A · August 4, 2026
Accumulated deficit as of June 30, 2026 was $497.2 million.
“As of June 30, 2026, we had an accumulated deficit of $497.2 million.”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2026-08-05 · Phase 3 Start — A Phase 3 randomized, double-blind, placebo-controlled study of subcutaneous nomlabofusp in Friedreich's ataxia subjects began.
Risks & what to watch (4)›
Key risks
- No approved products — Company has no product sales and expects none for several years, if at all [sec_mda · as of 2026-05-14].
- Large accumulated deficit — Accumulated deficit of $497.2M as of June 30, 2026, with ongoing net losses [sec_mda · as of 2026-08-04].
- Regulatory risk on surrogate endpoint — Accelerated approval depends on FDA acceptance of skin FXN as surrogate; safety database adequacy deferred to BLA review [sec_mda · as of 2026-03-19].
- Clinical trial delays — Unexpected delays could force expenditure reductions and extend cash burn [sec_mda · as of 2026-08-04].
What to watch
- Topline data from the open-label study expected in Q2 2026 [sec_mda · as of 2026-03-19].
- BLA submission for accelerated approval planned for June 2026 [sec_mda · as of 2026-03-19].
- Phase 3 confirmatory study (started August 2026) and its enrollment progress [catalyst].
- Cash runway and any additional capital raises, given $92.7M cash as of June 30, 2026 [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Larimar Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Larimar Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.30
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~12d
1 buy · 0 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
162
Total value held
$393.6M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 35,606,974 | $160.2M |
| blue owl capital holdings lp | 7,120,007 | $32.0M |
| blackrock, inc. | 3,752,200 | $16.9M |
| millennium management llc | 3,625,278 | $16.3M |
| aigh capital management llc | 3,000,000 | $13.5M |
| driehaus capital management llc | 2,934,399 | $13.2M |
| vanguard capital management llc | 2,866,349 | $12.9M |
| dafna capital management llc | 2,029,164 | $9.1M |
| goldman sachs group inc | 1,561,585 | $7.0M |
| deep track capital, lp | 1,500,000 | $6.8M |
Showing top 10 of 162 institutional holders of Larimar Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 12.4%
- Days to cover
- 6.2
- Shares short
- 8,309,598
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LRMR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Larimar Therapeutics, Inc.?
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a protein replacement therapy for Friedreich's ataxia, with regulatory designations for accelerated approval and a Phase 3 trial underway.
What is Larimar Therapeutics, Inc.'s next catalyst?
Larimar Therapeutics, Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia" — expected October 26, 2026.
Who is the CEO of Larimar Therapeutics, Inc.?
Dr. Carole S. Ben-Maimon M.D. is the chief executive officer of Larimar Therapeutics, Inc. (LRMR).
Where is Larimar Therapeutics, Inc. headquartered?
Larimar Therapeutics, Inc. (LRMR) is headquartered in Bala Cynwyd, PA, United States.
What therapeutic areas does Larimar Therapeutics, Inc. focus on?
Larimar Therapeutics, Inc. develops therapies across Rare Disease, Neurology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.